Between 2009 and 2013, healthcare market received 48 promises of improved quality of life among cancer patients. A team of researchers wanted to see the follow-up of these commitments. Therefore, they did a study on their performance. The conclusions indicate that most cancer drugs record no significant change in patients’ wellbeing.
Researchers Assessed Drug Efficiency at the Time of Their Approval and After Certain Timeframe
The European Medicines Agency is in charge of reviewing and approving new pills and treatments that can contribute to a better health care system. A study published in the British Medical Journal took a better look at this kind of admission process. The research focused on the oncological department. Their findings uncovered an almost empty pharmaceutical evolution in this area.
Researchers investigated the progress the new drugs scored at the time of their appearance on pharmacy shelves. It turned out that drug makers couldn’t support their efficiency in two-thirds of the promised improvements with evidence. There were no condition changes in study participants to attest better survival chances.
Only 10% of drug uses managed to record progress in patients’ quality of life. An average of 57% of uses couldn’t provide proves for bringing any health benefits to people.
After this initial stage, researchers assessed the progress these 48 cancer drugs scored over time. However, this section didn’t include satisfactory results as well. One of the authors, Huseyin Naci, claimed that the European Medicines Agency has different priorities when rating new drugs.
“What we find very surprising is that not very many studies are looking at overall survival or quality of life as their [primary]objective.”
Therefore, the study took a look at the evolution of these treatments in time. With an average of 5.4 years since drugs’ release, researchers followed up on their progress. The conclusions pointed out that only 35% of them proved to be a significant help for cancer patients. Other 33% of them came back with inconclusive results.
Oncology Needs Numerous Available Cancer Drugs to Record Faster Breakthroughs
Several researchers used this paper to signal a dire need for a more thorough admission process. On the other hand, the director of policy at Cancer Research UK, Emma Greenwood, voiced out a different view. The oncological department necessitates fast drug availability.
Patients usually don’t have much time at disposal. Their health condition deteriorates quickly, or drugs need prolong time to become effective. Therefore, giving the green light to treatments fast and recording data on their performance on the go represent the sole shortcuts to successful breakthroughs in the oncological world.
Image source: 1